Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous adipose-derived mesenchymal stem cells (AD-MSCs) is a cell therapy being developed by the Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus for the treatment of urinary incontinence, particularly in men following prostatectomy. The therapy involves the isolation of mesenchymal stem cells from the patient's own adipose tissue, which are then expanded and mixed with a collagen gel. This mixture is injected submucosally into the urethral area to promote tissue regeneration and improve the structural integrity and function of the urinary sphincter. The collagen gel acts as a scaffold to support the survival and integration of the stem cells at the injection site.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells (Institute of Biophysics and Cell Engineering).